Ofir Cohen

This study develops a bispecific antibody that enhances T-cell engagement with AXL+ cells, improving anti-PD-1 therapy efficacy in HNSCC by remodeling the tumor microenvironment.

SlideCNA detects spatial copy number alterations from Slide-seq data to identify sub-clones in metastatic breast cancer.

The paper develops a toolbox for scRNA-Seq and snRNA-Seq of fresh and frozen human tumors, testing it across eight tumor types and optimizing protocols for different tissue characteristics.

This study finds that 5% of breast cancers have high tumor mutation burden, more common in metastatic tumors, with APOBEC activity as the most common mutational process and potential benefit from PD-1 inhibitors.